Teknova Reports Second Quarter 2022 Financial Results
Alpha Teknova reported a total revenue of $11.7 million for Q2 2022, representing a 41% year-over-year increase. The company maintains a cash position of $64.7 million to support ongoing growth investments and has adjusted its 2022 revenue outlook to $38-42 million. Although they experienced healthy demand, Teknova acknowledges potential revenue slowdown in H2 2022 due to biopharma customers deferring purchases. Gross profit reached $5.2 million, with a 44.9% gross margin, despite increased operating expenses of $11.9 million and a net loss of $6.2 million.
- Total revenue up 41% year-over-year to $11.7 million.
- Cash position of $64.7 million supports growth.
- 2022 revenue outlook adjusted to $38-42 million, indicating continued growth.
- Net loss of $6.2 million for Q2 2022, worsened from loss of $2.3 million in Q2 2021.
- Operating expenses increased to $11.9 million, up from $5.9 million in Q2 2021.
- Higher labor and overhead costs leading to gross margin decline.
Second quarter 2022 total revenue was
Cash position of
Company updates 2022 revenue outlook to
HOLLISTER, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2022.
“We were pleased with our second quarter revenue growth and the excellent progress on the build-out of our new manufacturing facility,” said Stephen Gunstream, President and CEO of Teknova. “While we continue to see healthy demand across our broader customer base, we now expect lower than anticipated revenue in the second half of 2022, we believe in large part due to certain of our early-stage biopharma customers deferring large purchases. We nonetheless remain confident in our fundamental growth opportunity and our position in the market.”
Corporate and Financial Updates
- Achieved record quarterly total revenue of
$11.7 million , up41% , compared to$8.3 million in the second quarter 2021 - Remained on track with capacity expansion of existing facilities and the construction of a new, state-of-the-art manufacturing facility
- Reported cash position of
$64.7 million , supporting ongoing investment in future growth
Revenue for the Second Quarter and Year-to-Date 2022
| (Dollars in Thousands) | For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||
| Unaudited | 2022 | 2021 | 2022 | 2021 | ||||||||
| Lab Essentials | $ | 8,393 | $ | 6,456 | $ | 15,368 | $ | 13,246 | ||||
| Clinical Solutions | 2,943 | 1,593 | 6,755 | 2,664 | ||||||||
| Sample Transport | — | 37 | 6 | 961 | ||||||||
| Other | 354 | 227 | 708 | 520 | ||||||||
| Total Revenue | $ | 11,690 | $ | 8,313 | $ | 22,837 | $ | 17,391 | ||||
Second Quarter 2022 Financial Results
Total revenue for the second quarter 2022 was
Gross profit for the second quarter 2022 was
Operating expenses for the second quarter 2022 were
Net loss for the second quarter 2022 was
Cash used in operating activities for the second quarter 2022 was
Adjusted EBITDA for the second quarter 2022 was negative
2022 Revenue Outlook
Teknova now anticipates total revenue of
Conference Call and Webcast
Teknova will host a webcast and conference call on Wednesday, August 10, 2022, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/s88ivr8z. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BI212f2574e2aa4cf68a5e40a4de877e89. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of our business and the effectiveness of our business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, benefit from income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that we do not consider representative of our ongoing operating performance.
Teknova defines Free Cash Flow as cash used in operating activities less purchases of property, plant, and equipment.
Teknova presents Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in our industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in our operating results because they exclude items that are not indicative of our core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to our anticipated total revenue, our expectation that recent customer engagement dynamics will be transitory, and growth in Lab Essentials and growth in Clinical Solutions for 2022, and statements about our prospects and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, demand for our products (including the delay or pausing of customer orders); our assessment of fundamental indicators of future demand across our target customer base; our ability to expand our production capacity and commercial and R&D capabilities; our cash flows and revenue growth rate; our supply chain, sourcing, manufacturing and warehousing; inventory management; risks related to global economic and marketplace uncertainties related to the impact of the COVID-19 pandemic, including the impact of the pandemic on our supply chain; reliance on a limited number of customers for a high percentage of our revenue; potential acquisitions and integration of other companies and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
ALPHA TEKNOVA, INC.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | $ | 11,690 | $ | 8,313 | $ | 22,837 | $ | 17,391 | ||||||||
| Cost of sales | 6,443 | 4,959 | 12,241 | 9,012 | ||||||||||||
| Gross profit | 5,247 | 3,354 | 10,596 | 8,379 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,929 | 851 | 3,942 | 1,548 | ||||||||||||
| Sales and marketing | 2,598 | 904 | 4,195 | 1,609 | ||||||||||||
| General and administrative | 7,059 | 3,838 | 14,354 | 8,002 | ||||||||||||
| Amortization of intangible assets | 287 | 287 | 574 | 574 | ||||||||||||
| Total operating expenses | 11,873 | 5,880 | 23,065 | 11,733 | ||||||||||||
| Loss from operations | (6,626 | ) | (2,526 | ) | (12,469 | ) | (3,354 | ) | ||||||||
| Other income (expenses), net | ||||||||||||||||
| Interest income (expense), net | 28 | (304 | ) | 15 | (296 | ) | ||||||||||
| Other expense, net | — | (3 | ) | — | (2 | ) | ||||||||||
| Total other income (expenses), net | 28 | (307 | ) | 15 | (298 | ) | ||||||||||
| Loss before income taxes | (6,598 | ) | (2,833 | ) | (12,454 | ) | (3,652 | ) | ||||||||
| Benefit from income taxes | (395 | ) | (583 | ) | (754 | ) | (747 | ) | ||||||||
| Net loss | $ | (6,203 | ) | $ | (2,250 | ) | $ | (11,700 | ) | $ | (2,905 | ) | ||||
| Net loss per share—basic and diluted | $ | (0.22 | ) | $ | (0.52 | ) | $ | (0.42 | ) | $ | (0.73 | ) | ||||
| Weighted average shares used in computing net loss per share—basic and diluted | 28,057,801 | 4,328,222 | 28,044,460 | 3,965,741 | ||||||||||||
ALPHA TEKNOVA, INC.
Condensed Balance Sheets
(Unaudited)
(In thousands)
| As of June 30, | As of December 31, | ||||||
| 2022 | 2021 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 64,734 | $ | 87,518 | |||
| Accounts receivable, net | 5,810 | 4,666 | |||||
| Inventories, net | 7,909 | 5,394 | |||||
| Income taxes receivable | 117 | 1,188 | |||||
| Prepaid expenses and other current assets | 1,701 | 2,438 | |||||
| Total current assets | 80,271 | 101,204 | |||||
| Property, plant and equipment, net | 47,258 | 29,810 | |||||
| Operating right-of-use lease assets | 19,154 | — | |||||
| Goodwill | 16,613 | 16,613 | |||||
| Intangible assets, net | 18,130 | 18,704 | |||||
| Other non-current assets | 769 | 180 | |||||
| Total assets | $ | 182,195 | $ | 166,511 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,421 | $ | 2,248 | |||
| Accrued liabilities | 8,250 | 5,495 | |||||
| Current portion of operating lease liabilities | 2,194 | — | |||||
| Total current liabilities | 11,865 | 7,743 | |||||
| Deferred tax liabilities | 2,402 | 3,153 | |||||
| Other accrued liabilities | 233 | 273 | |||||
| Long-term debt, net | 16,818 | 11,870 | |||||
| Deferred rent | — | 269 | |||||
| Long-term operating lease liabilities | 17,410 | — | |||||
| Total liabilities | 48,728 | 23,308 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock | — | — | |||||
| Common stock | — | — | |||||
| Additional paid-in capital | 152,705 | 150,741 | |||||
| Accumulated deficit | (19,238 | ) | (7,538 | ) | |||
| Total stockholders’ equity | 133,467 | 143,203 | |||||
| Total liabilities and stockholders’ equity | $ | 182,195 | $ | 166,511 | |||
ALPHA TEKNOVA, INC.
Condensed Statements of Cash Flows
(Unaudited)
(In thousands)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Operating activities: | ||||||||||||||||
| Net loss | $ | (6,203 | ) | $ | (2,250 | ) | $ | (11,700 | ) | $ | (2,905 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||
| Bad debt expense | 25 | 319 | 32 | 231 | ||||||||||||
| Inventory reserve | (4 | ) | 701 | (8 | ) | 699 | ||||||||||
| Depreciation and amortization | 792 | 700 | 1,543 | 1,352 | ||||||||||||
| Stock-based compensation | 934 | 302 | 1,721 | 485 | ||||||||||||
| Deferred taxes | (391 | ) | (583 | ) | (751 | ) | (747 | ) | ||||||||
| Amortization of debt financing costs | 53 | 46 | 99 | 46 | ||||||||||||
| Non-cash lease expense | 75 | 49 | 181 | 49 | ||||||||||||
| Other | — | 4 | — | (6 | ) | |||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||
| Accounts receivable | 143 | (66 | ) | (1,176 | ) | 334 | ||||||||||
| Inventories | (1,479 | ) | (702 | ) | (2,507 | ) | (997 | ) | ||||||||
| Income taxes receivable | 1,071 | (44 | ) | 1,071 | (221 | ) | ||||||||||
| Prepaid expenses and other current assets | 190 | 70 | 737 | 418 | ||||||||||||
| Accounts payable | (515 | ) | (1,316 | ) | (278 | ) | (33 | ) | ||||||||
| Accrued liabilities | (136 | ) | (642 | ) | 626 | 205 | ||||||||||
| Other | (393 | ) | (139 | ) | (629 | ) | (60 | ) | ||||||||
| Cash used in operating activities | (5,838 | ) | (3,551 | ) | (11,039 | ) | (1,150 | ) | ||||||||
| Investing activities: | ||||||||||||||||
| Purchase of property, plant and equipment | (10,920 | ) | (4,674 | ) | (16,837 | ) | (8,558 | ) | ||||||||
| Proceeds from loan to related party | — | — | — | 529 | ||||||||||||
| Proceeds on sales of short-term marketable securities | — | — | — | 1,132 | ||||||||||||
| Proceeds from maturities of short-term marketable securities | — | — | — | 695 | ||||||||||||
| Cash used in investing activities | (10,920 | ) | (4,674 | ) | (16,837 | ) | (6,202 | ) | ||||||||
| Financing activities: | ||||||||||||||||
| Proceeds from long-term debt | 5,135 | — | 5,135 | 11,889 | ||||||||||||
| Payment of debt issuance costs | (151 | ) | — | (151 | ) | (153 | ) | |||||||||
| Payment of exit fee costs | (135 | ) | — | (135 | ) | — | ||||||||||
| Payment of costs related to initial public offering | — | (891 | ) | — | (2,349 | ) | ||||||||||
| Proceeds from initial public offering, net of underwriters’ commissions and discounts | — | 102,672 | — | 102,672 | ||||||||||||
| Proceeds from exercise of stock options | 44 | — | 99 | — | ||||||||||||
| Proceeds from issuance of common stock under employee stock purchase plan | 144 | — | 144 | — | ||||||||||||
| Cash provided by financing activities | 5,037 | 101,781 | 5,092 | 112,059 | ||||||||||||
| Change in cash and cash equivalents | (11,721 | ) | 93,556 | (22,784 | ) | 104,707 | ||||||||||
| Cash and cash equivalents at beginning of period | 76,455 | 14,466 | 87,518 | 3,315 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 64,734 | $ | 108,022 | $ | 64,734 | $ | 108,022 | ||||||||
ALPHA TEKNOVA, INC.
Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures
(Unaudited)
(In thousands)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net loss – as reported | $ | (6,203 | ) | $ | (2,250 | ) | $ | (11,700 | ) | $ | (2,905 | ) | ||||
| Add back: | ||||||||||||||||
| Interest income (expense), net | 28 | (304 | ) | 15 | (296 | ) | ||||||||||
| Benefit from income taxes | (395 | ) | (583 | ) | (754 | ) | (747 | ) | ||||||||
| Depreciation expense | 505 | 413 | 969 | 778 | ||||||||||||
| Amortization of intangible assets | 287 | 287 | 574 | 574 | ||||||||||||
| EBITDA | $ | (5,834 | ) | $ | (1,829 | ) | $ | (10,926 | ) | $ | (2,004 | ) | ||||
| Other and one-time expenses: | ||||||||||||||||
| Stock-based compensation expense | 934 | 302 | 1,721 | 485 | ||||||||||||
| Adjusted EBITDA | $ | (4,900 | ) | $ | (1,527 | ) | $ | (9,205 | ) | $ | (1,519 | ) | ||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Cash used in operating activities | $ | (5,838 | ) | $ | (3,551 | ) | $ | (11,039 | ) | $ | (1,150 | ) | ||||
| Purchase of property, plant and equipment | (10,920 | ) | (4,674 | ) | (16,837 | ) | (8,558 | ) | ||||||||
| Free Cash Flow | $ | (16,758 | ) | $ | (8,225 | ) | $ | (27,876 | ) | $ | (9,708 | ) | ||||
FAQ
What were Alpha Teknova's total revenues for Q2 2022?
What is the outlook for Teknova's revenue in 2022?
How much cash does Teknova have available for investment?
What was Teknova's net loss for Q2 2022?
What were the operating expenses for Teknova in Q2 2022?
